Skin sensitisation prediction using read-across, an illustrative next generation risk assessment (NGRA) case study for vanillin.

What was studied

Vanillin CAS121-33-5 is the exact target of the risk assessment. Prediction based on analogue selection and new-approach testing is not a clinical allergy prevalence study or universal safety conclusion.

Checked against the published abstract on Oct 1, 2026. Read the source ↗